Search PubMed⌕ Search

Biomedical subjects

G Buono

Publications and source records attributed to G Buono.

At least 19 recordsLinked to original sources
PubMed2005

Discrimination between closed and open forms of lipases using electrophoretic techniques.

The enhanced catalytic activity of lipases is often associated with structural changes. The three-dimensional (3D) structures showed that the covalently inhibited lipases exist under their open conformations, in contrast to their native closed forms. We studied the inhibition of various lipases--human and dog gastric lipases, human pancreatic lipase, and Humicola lanuginosa lipase--by the octyl-undecyl phosphonate inhibitor, and we measured the subsequent modifications of their respective electrophoretic mobility. Furthermore, the experimental values of the isoelectric points found for the native (closed) and inhibited (open) lipases are in agreement with theoretical calculations based on the electrostatic potential. We concluded that there is a significant difference in the isoelectric points between the closed (native) and open (inhibited) conformations of the four lipases investigated. Thus, analysis of the electrophoretic pattern is proposed as an easy experimental tool to differentiate between a closed and an open form of a given lipase.

Animals↗
PubMed2000

Beneficial Effect of ortho-Methoxy Groups in the Asymmetric Ring Opening of meso Epoxides with Silicon Tetrachloride Catalyzed by Chiral ortho-Methoxyphenyldiazaphosphonamide Lewis Bases We thank the CNRS for financial support. O.L. acknowledges the CNRS and Region PACA for a doctoral fellowship. We thank Dr. M. Giorgi and Prof. M. Pierrot for their kind assistance with the X-ray analysis of compound 1 and Dr. A. Tenaglia for fruitful discussions.

Explore the source record for details and available documents.

Journal Article↗
PubMed2000

Surface properties of unsaturated non-oxidized and oxidized free fatty acids spread as monomolecular films at an argon/water interface.

The interfacial properties of monomolecular films of stearic acid (SA) oleic acid (OA), linoleic acid (LA), ricinoleic acid (RA), 13(S)-hydroperoxyoctadeca-9Z,11E-dienoic acid (13-HPODE) and 13(S)-hydroxyoctadeca-9Z,11E-dienoic acid (13-HODE) were studied by recording the changes occurring in response to monomolecular film compression in their surface pressure and surface potential at the argon/water interface. The oxidized free fatty acids are more expanded than the parent non-oxidized free fatty acids, reflecting a higher hydrophilic-lipophilic balance. The lift-off values of the molecular area of 13-HODE, 13-HPODE and RA were 68, 74 and 106 A2 molecule(-1), respectively, as compared to 47 and 40 A2 molecule(-1) in the case of LA and OA, respectively. Variations in the molecular orientation of free fatty acids can result in large changes in the dipole moment which are not accompanied by appreciable changes in the surface pressure. In the case of the oxidized free fatty acids, the spontaneous desorption into the aqueous phase was found to increase at increasing surface pressures. The desorption rates of OA and LA increased dramatically in the presence of beta-cyclodextrin (beta-CD); whereas the presence of beta-CD only slightly increased the desorption rates of the oxidized free fatty acids.

Argon↗
PubMed2000

Covalent inhibition of digestive lipases by chiral phosphonates.

Designing and synthesizing specific inhibitors is of fundamental value for understanding the molecular mechanisms involved in the interfacial adsorption step as well as the catalytic activity of lipases. In this Account, we will review and discuss results obtained mostly at our laboratory concerning the covalent inhibition of human gastric and human pancreatic lipases by chiral phosphonates. Rather than presenting an exhaustive list of compounds tested so far with lipases of animal and microbial origin, we selected recent experimental data illustrating well the specific problems encountered during the covalent inhibition of these digestive lipases.

Enzyme Inhibitors↗
PubMed1999

Inhibition of human gastric and pancreatic lipases by chiral alkylphosphonates. A kinetic study with 1,2-didecanoyl-sn-glycerol monolayer.

Enantiomerically pure alkylphosphonate compounds RR'P(O)PNP (R = CnH2n + 1, R' = OY with Y = Cn'H2n' + 1 with n = n' or n not equal to n'; PNP = p-nitrophenoxy) noted (RY), mimicking the transition state occurring during the carboxyester hydrolysis were synthesized and investigated as potential inhibitors of human gastric lipase (HGL) and human pancreatic lipase (HPL). The inhibitory properties of each enantiomer have been tested with the monomolecular films technique in addition to an enyzme linked immunosorbent assay (ELISA) in order to estimate simultaneously the residual enzymatic activity as well as the interfacial lipase binding. With both lipases, no obvious correlation between the inhibitor molar fraction (alpha 50) leading to half inhibition, and the chain length, R or Y was observed. (R11Y16)s were the best inhibitor of HPL and (R10Y11)s were the best inhibitors of HGL. We observed a highly enantioselective discrimination, both with the pure enantiomeric alkylphosphonate inhibitors as well as a scalemic mixture. We also showed, for the first time, that this enantioselective recognition can occur either during the catalytic step or during the initial interfacial adsorption step of the lipases. These experimental results were analyzed with two kinetic models of covalent as well as pseudo-competitive inhibition of lipolytic enzymes by two enantiomeric inhibitors.

Chromatography, High Pressure Liquid↗
PubMed1995

The 2.46 A resolution structure of the pancreatic lipase-colipase complex inhibited by a C11 alkyl phosphonate.

Pancreatic lipase belongs to the serine esterase family and can therefore be inhibited by classical serine reagents such as diisopropyl fluoride or E600. In an attempt to further characterize the active site and catalytic mechanism, we synthesized a C11 alkyl phosphonate compound. This compound is an effective inhibitor of pancreatic lipase. The crystal structure of the pancreatic lipase-colipase complex inhibited by this compound was determined at a resolution of 2.46 A and refined to a final R-factor of 18.3%. As was observed in the case of the structure of the ternary pancreatic lipase-colipase-phospholipid complex, the binding of the ligand induces rearrangements of two surface loops in comparison with the closed structure of the enzyme (van Tilbeurgh et al., 1993b). The inhibitor, which could be clearly observed in the active site, was covalently bound to the active site serine Ser152. A racemic mixture of the inhibitor was used in the crystallization, and there exists evidence that both enantiomers are bound at the active site. The C11 alkyl chain of the first enantiomer fits into a hydrophobic groove and is though to thus mimic the interaction between the leaving fatty acid of a triglyceride substrate and the protein. The alkyl chain of the second enantiomer also has an elongated conformation and interacts with hydrophobic patches on the surface of the open amphipathic lid. This may indicate the location of a second alkyl chain of a triglyceride substrate. Some of the detergent molecules, needed for the crystallization, were also observed in the crystal. Some of them were located at the entrance of the active site, bound to the hydrophobic part of the lid. On the basis of this crystallographic study, a hypothesis about the binding mode of real substrates and the organization of the active site is proposed.

Binding Sites↗
PubMed1994

Digestive lipases: inactivation by phosphonates.

Phosphonates mimicking the transition state which occurs during carboxyester hydrolysis were synthesized and investigated as potential inactivators of human pancreatic (HPL) and gastric (HGL) lipases. Their efficiency as inactivators was studied on the basis of the alkyl chain length, the nature of the leaving group and the influence of the ester substituent. In each case, HGL was found to be more sensitive than HPL towards these phosphonates. The released p-nitrophenol to enzyme ratio indicates that a 1:1 complex was formed. In the absence of substrate, the most powerful inactivator was O-methyl O-(p-nitrophenyl) n-pentylphosphonate (4A), which has a short alkyl chain, a small methoxy substituent and a good leaving group.

Enzyme Activation↗
PubMed1987

Lipase-catalyzed reactions in organic media: competition and applications.

Lipases (triacylglycerol acylhydrolase, EC 3.1.1.3) have been used in organic media for the catalysis of reactions such as hydrolysis, esterification and transesterification. In these conditions it was confirmed that all reactions proceed through an acyl enzyme intermediate in two successive steps: acyl enzyme formation and solvolysis. The competition between two acyl acceptors (acyl donors) for reaction with a donor (acceptor) is described for the first time. A kinetic model is proposed using a competitive factor which is in good accordance with experimental results. The model was used successfully for the prediction of alcohol (acid) separations and resolutions by lipases.

Alcohols↗
PubMed1986

Early-onset myasthenia gravis.

Signs of myasthenia gravis developed by age 3 years in 11 children. Six of these patients had persistent neonatal myasthenia gravis, a familial abnormality of neuromuscular transmission that is not immunologically mediated. Five patients had juvenile onset myasthenia gravis, an autoimmune disorder similar to myasthenia gravis in adults. Autoimmune myasthenia has rarely been recognized by age 3 years, but the presence of five cases in our series suggests that the disorder may be more common in young children than once believed. The development of anti-acetylcholine receptor antibody assays makes it easier to distinguish autoimmune myasthenia gravis from the congenital forms. This distinction is important, because the prognosis, treatment, and risk of recurrence in family members is different for each type of myasthenia.

Antibodies↗
PubMed1986

Cow's milk hypersensitivity in an elderly woman: clinical and immunologic findings.

We report a case of allergy to cow's milk diagnosed in a 79-year-old woman, who had the habit of drinking large amounts of milk and other dairy products for several years. She had been an asthmatic since the age of 40. At age 65, she noticed a correlation between cheese and milk intake and onset of asthma and two episodes of shock, and she has been avoiding milk for the past 15 years. Positive skin prick tests for cow's milk proteins, grass pollens, and house dust mite were observed. Serum IgE levels were above 3,000 U/mL, with high molecular weight IgE detected by gel chromatography. RAST results confirmed the presence of sensitizations detected by skin prick tests. The patient never suffered from atopic eczema. This unusual case of food allergy with onset after the age of 40 may indicate that prolonged exposure to food antigens in predisposed individuals may lead to the development of allergy even in adult age, lasting for decades after partial elimination of the allergen from the diet.

Aged↗
PubMed1983

Adjuvant effects of a crystalline silica on IgE and IgG1 antibody production in mice and their prevention by the macrophage stabilizer poly-2-vinylpyridine N-oxide.

A crystalline silica (standard quartz DQ12 with particle size less than 5 microns) is able to stimulate in Balb/c mice the production of IgE and IgG1 antibody to a single 1-microgram dose of ovalbumin. The adjuvant effects of silica on both IgE and IgG1 antibody production are prevented by pretreatment of animals with poly-2-vinylpyridine N-oxide, a polymer that protects macrophages from the well-documented toxic effects of silica. These results indicate that adjuvanticity of silica is, at least partly, correlated to the damage induced on macrophages.

Adjuvants, Immunologic↗
PubMed1977

[Long-term clinical study of a new molecule (nifedipine) in ischemic cardiopathy].

Results with a new anti-angina molecule (nifedipine: Adalat) in the long-term management of 28 patients with ischaemic heart disease are presented. The effectiveness of the drug was judged outstanding on the strength of its reduction of angina outstanding on the strength of its reduction of angina crises and consumption of NTG beads. Non side-effects were noted.

Adult↗